Form SCHEDULE 13G/A Cardiol Therapeutics Filed by: Tejara Capital Ltd

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Tejara Capital Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,382,551.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,382,551.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Fund Manager authorised by FCA in UK

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Cardiol Therapeutics Inc.

(b)

Address of issuer's principal executive offices:

602-2265 UPPER MIDDLE ROAD EAST, 602-2265 UPPER MIDDLE ROAD EAST, OAKVILLE, ONTARIO, CANADA, L6H 0G5.

Item 2.

(a)

Name of person filing:

i. Trefoil Select Funds SPC-Stylus SP ii. Tejara Capital Limited

(b)

Address or principal business office or, if none, residence:

i. C/O Apex Funds Services Cayman Ltd, 3rd Floor, Citrus Gove Building, 106 Goring Ave, Grand Cayman, George Town KY1-1001, Cayman Islands ii. 4th Floor, 40 Grosvenor Gardens, London SW1W 0EB, United Kingdom

(c)

Citizenship:

i. Cayman ii. United Kingdom

(d)

Title of class of securities:

Class A Common Shares

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Tejara Capital Limited is authorised by FCA in UK as a fund manager and it manages the fund Trefoil Select Funds SPC- Stylus SP, that is registered in Cayman

Item 4.

Ownership

(a)

Amount beneficially owned:

6,382,551

(b)

Percent of class:

5.3 %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0

(ii) Shared power to vote or to direct the vote:

0

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

6,382,551

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a fund manager authorised and regulated by the FCA in the UK is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Tejara Capital Ltd

Signature:	Miyan Mansur Mannan
Name/Title:	DIRECTOR
Date:	09/23/2026

Form SCHEDULE 13G/A Cardiol Therapeutics Filed by: Tejara Capital Ltd

You May Also Be Interested In

Create E-mail Alert Related Categories

Related Entities

Sign up for StreetInsider Free!

Free News Feed